Abstract 4592
Background
Ostracism is defined as being ignored or excluded by others. Being excluded during adolescence can result in various problem behaviors and emotional disturbances. The purpose of the study is to evaluate ostracism in adolescent cancer patients and define the predictors of it.
Methods
The study was conducted as a multicenter survey study. Adolescent cancer patients, who were under remission, were evaluated with structured questionnaires to assess the Ostracism and clinical parameters associated with it. Turkish version of Ostracism Experience Scale for Adolescents (OES-A) and Kutcher adolescent depression scale (KADS) were used.
Results
Between December 2017 and April 2018, 52 patients were evaluated in 4 different cancer centers. Median age was 21 (14-24), 40.4% of them were female and most of them were university student (23, 44.2%). Median OES-A score was 23.5(11.0-41.0). While female sex (28.0 vs 19.0, p = 0.008) and low family income (28.0 vs 21.0, p = 0.02) were associated with more ostracization; patients working full/part time (19.0 vs 25.0, p = 0.01) and university students (19.0 vs 27.0, p = 0.01) were less ostracized. In multivariate analysis, being female was associated with high OES-A scores (OR: 7.8, CI(95%) 1.4-42.9, p = 0.018). Being university student (OR: 0.14, , CI(95%) 0.02- 0.71, p = 0.018) and working (OR: 0.07 , CI(95%) 0.007- 0.7, p = 0.02) were associated with low OES-A scores(Table). Higher OES-A scores were associated with high KADS scores (9.0 vs 7.5, p = 0.16).Table: 1543P
| High OES-A Score | |||
|---|---|---|---|
| Characteristics | OR | CI (95%) | p |
| Female | 7.8 | 1.4- 42.9 | 0.018 |
| Low income | 3.2 | 0.6-16.3 | 0.14 |
| University student | 0.14 | 0.02-0.71 | 0.018 |
| Working | 0.07 | 0.007- 0.7 | 0.02 |
Conclusions
It is the first data about ostracism in adolescent cancer patients. OES-A score was higher than the scores of adolescents without cancer. While female adolescent patients were found to be under risk of ostracism, working and being university student were protective against ostracism. Ostracism in adolescent cancer patients should be studied in larger series.
Clinical trial identification
Legal entity responsible for the study
Ali Alkan.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract